Expand EYPT Menu
EYPT MENU

EYPT Latest Press Releases

-- August 5, 2026 --

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments Globe Newswire 7:00 AM

-- July 30, 2026 --

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) Globe Newswire 7:00 AM

-- July 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- July 13, 2026 --

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer Globe Newswire 7:00 AM

-- June 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- May 19, 2026 --

EyePoint Announces Participation at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- May 18, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- May 14, 2026 --

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU , Building Confidence Ahead of Mid-2026 Topline Data Globe Newswire 7:00 AM

-- May 6, 2026 --

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments Globe Newswire 7:00 AM

-- April 29, 2026 --

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 Globe Newswire 7:00 AM

-- April 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- March 16, 2026 --

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes